QGEN - キアゲン （Qiagen N.V.）

ANGLE plc STUDY USING PARSORTIX DEMONSTRATES IMPORTANCE OF BIOMARKER-INDEPENDENT CTC ISOLATION IN HEAD AND NECK CANCER EMT status of CTCs found to provide additional insight to tumour tissue biopsy Potential role of CTC EMT biomarkers as therapeutic targets GUILDFORD, UK / ACCESSWIRE / September 28, 2022 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the University of Birmingham has published the results of a study undertaken in head and neck squamous cell carcinoma (HNSCC) which characterised the epithelial-mesenchymal transition (EMT) status of circulating tumour cells (CTCs). EMT is clinically significant due to its role in tumour progression and invasion, the development of metastasis, metabolic reprogramming, immune evasion, and resistance of cancer cells to therapy. The study used the Parsortix ® system to harvest CTCs from peripheral blood samples from 20 treatment-naïve HNSCC patients at baseline prior to surgery.

WILMINGTON, DE / ACCESSWIRE / September 26, 2022 / Transparency Market Research Inc. - Rising use of automation in various healthcare and biotech research processes is creating attractive opportunities in the global molecular diagnostics market . This trend is further bolstered by the rising need for incorporating automation for facilitating various processes, including extraction of DNA, amplification, and analyzing and recording healthcare data. These automated systems offer various benefits, such as higher efficiency, precise output, and reduced time required for gaining results. Based on a recent research report, the global molecular diagnostics market is estimated to rise at a CAGR of 11.1% over the forecast period of 2021 to 2028. Get Exclusive PDF Sample Copy of Molecular Diagnostics Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1783 Growing adoption of molecular diagnostic devices in various diagnostic laboratories, biotech and pharma companies, hospitals, and research and academic institutes is creating growth opportunities for players in the global molecular diagnostics market in developed economies.

The major players in the molecular diagnostics market are Becton, BioMérieux SA. , Danaher Corporation, Grifols, Hologic Inc. , Novartis AG, QIAGEN, Siemens Healthcare GmbH, Abbott, and Dickinson and Company. The major players in the molecular diagnostics market are Becton, BioMérieux SA. , Danaher Corporation, Grifols, Hologic Inc. , Novartis AG, QIAGEN, Siemens Healthcare GmbH, Abbott, and Dickinson and Company.

Major players in the microfluidics market are Illumina, Inc. , PerkinElmer, Inc. , Agilent Technologies, Inc. , Abbott Laboratories, Thermo Fisher Scientific, Qiagen, Elveflow, Cellix Ltd. , Fluidigm Corporation, Fluigent SA, Zeon Corporation, Innovative Biochips, LLC, Dolomite Microfluidics, Idex Corporation, and UFluidix. Major players in the microfluidics market are Illumina, Inc. , PerkinElmer, Inc. , Agilent Technologies, Inc. , Abbott Laboratories, Thermo Fisher Scientific, Qiagen, Elveflow, Cellix Ltd. , Fluidigm Corporation, Fluigent SA, Zeon Corporation, Innovative Biochips, LLC, Dolomite Microfluidics, Idex Corporation, and UFluidix.

Pune, India, Sept. 21, 2022 (GLOBE NEWSWIRE) -- The global biomarkers market size was USD 39.10 billion in 2018 and is expected to reach USD 97.51 billion by 2026, exhibiting a CAGR of 12.1% over the forecast period. The rise can be attributed to an escalation in the diagnostic applications of biomarkers. This is further being supplemented by the growing prevalence of cancer and an increase in the number of research and development activities. Key Industry Development: May 2021 – QIAGEN N.V. rolled out its tissue companion diagnostic approved by the FDA. The solution was released for identifying the mutation of KRAS G12C in NSCLC tumors. The diagnostic would help in the expansion of precision medicine portfolio for lung cancer. Get a Sample PDF Brochure: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/biomarkers-market-102173 Report Scope: Report Coverage Details Forecast Period 2019 to 2026 Forecast Period 2019 to 2026 CAGR 12.1% 2026 Value Projection USD 97.51 billion Base Year 2018 Market Size in 2018 USD 39.

NEW HAVEN, Conn., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO ) , welcomes Sharon Robins as the Company''s Senior Director of Laboratory & Hospital Sales for the Product''s Division. As the Company launches HemeScreen with ThermoFisher and its 200+ member sales force, and with the goal of Thermo meeting its first-year target of $10M in revenues (annualized run rate), Ms. Robins will be tasked with managing that relationship and ensuring its success. Coming from Qiagen, a market leader in the diagnostic reagents field, Ms. Robins brings with her a strong background in multiple leadership positions in diagnostic product sales. During her tenure at Qiagen she was responsible for over $100M in annual revenues. Sharon has a strong background in diagnostics distribution, previously holding senior sales positions at Quest Diagnostics, ThermoFisher, and Life Technologies. In those roles she led teams and was responsible for triple-digit million-dollar revenues. "We are extremely fortunate to have attracted an executive of Sharon''s caliber to our company.

New products posted to GenomeWeb for the week of Aug. 15, 2022.

Greenhouse gas emissions intensity lowered by 16% and plastic footprint down 9.6% vs. 2020 Commitment to ambitious climate goals: Net-zero by 2050, Scope 1 and 2 emissions down 42% by 2030 Widenin…

VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today released its 2021 Sustainability Report, outlining significant achievements in the areas of Environment, Social and Governance (ESG) as part of its strategy to become a stronger and more sustainable leader in providing Sample to Insight solutions that unlock valuable molecular insights for customers in the Life Science and Molecular Diagnostics industries. “As the world faces key challenges, from i

Qiagen (QGEN) on Monday launched a syndromic test to differentiate between monkeypox and five other pathogens that produce similar symptoms.The Germany-based molecular testing…

GERMANTOWN, Md., & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #lifescience--QIAGEN launches the Workflow Configurator to help life science researchers simplify and optimize their laboratory experiments

Die Qiagen-Aktie notiert am Mittwoch etwas fester. Das Papier kostete zuletzt 42,57 Euro. Ein Kursgewinn in Höhe von 17 Cent erfreut derzeit die Aktionäre von Qiagen. Zur Stunde wird die Aktie am A

Global law firm White & Case LLP has advised Qatar Investment Authority (QIA), the sovereign wealth fund of the State View post on CompanyNewsHQ : White & Case Advises QIA on Participation in Age of Learnings US$300 Million Financing Round | White & Case LLP

Der Kurs der dem Anteilsschein von Qiagen kommt kaum von der Stelle. Zuletzt zahlten Investoren für die Aktie 41,34 Euro. Die Wertschätzung der Börsenteilnehmer für die Qiagen-Aktie hat sich heute

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 02.07.2021 / 22:04 The issuer is solely responsible f